Active substance: Phenibutum

Indications: asthenic and anxiously neurotic states; insomnia and night unrest in elderly patients; prevention of stress condition prior to operations; Meniere’s disease and vertigo, which is associated with dysfunction of vestibular analyser of various origins; prevention of kinetosis; stammering and ticks in children; auxiliary medication for the relief of alcohol abstinence syndrome.

Dose and quantity: 250 mg N20, 100 mg N15

Pharmaceutical form: tablets, powder for the preparation of a liquid for external use.

ATC Code: N06BX22

Nootropic agent

The active substance of Noofen® – phenibut can be considered to be a derivative of γ – aminobutyric acid (GABA), as well as β – phenylethylamine.  In addition to nootrophic action, Noofen® also has a tranquillising effect.


In adults:

Doses and therapies are determined individually. See the summary of product characteristics for more detailed information.

Powder form must be used in children under 8 years of age.

In children from 8 to 14 years of age:

250 mg three times per day. The duration of the therapy course – 26 weeks.

In children from 3 to 7 years of age:

100 mg 2 – 3 times per day.


Advertising intended for specialists only.

Summary of Product Characteristics

The advertiser: AS Olainfarm, Olaine, Rūpnīcu iela 5, LV-2114. Material prepared: February 2020.